| P/E (FY) | 13.6 | Sales (TTM) | NOK 152.1M |
| Earnings (TTM) | NOK 45.3M | ROE | 26.59% |
| Net Margin | 29.78% | ROIC | 18.68% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 14.99% |
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for medical diagnostics and research in the United States, Asia, and Europe. Its in-vitro diagnostic reagents for clinical chemistry analyzers include immunoassays for calprotectin, cystatin C, retinol-binding protein, and canine C-reactive protein, plus faecal calprotectin and pancreatic elastase tests that support diagnosis of conditions such as inflammatory bowel disease and pancreatic exocrine insufficiency. Founded in 2001, it is headquartered in Moss, Norway.
| Market Cap | — | Trading Days | 2368 |
| 52W High | 60.00 |
| 52W Low | 33.50 |
| % Off High | −35.00% |
| YTD | −29.91% | 1Y | −32.54% |
| 3Y | −15.72% | 5Y | −36.24% |
| Since incept. (ann.) | 4.45% |
| Ann. Volatility (1Y) | 52.14% | Ann. Volatility (3Y) | 48.17% |
| Sharpe (1Y) | −0.42 | Sharpe (3Y) | 0.12 |
| Max Drawdown (1Y) | −40.76% | Max Drawdown (3Y) | −43.44% |
| Beta (3Y, vs SPY) | 0.67 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LLY | ELI LILLY & Co | $1.09T | 50.3 |
| JNJ | JOHNSON & JOHNSON | $616.50B | 23.2 |
| ONC | BeOne Medicines Ltd. | $465.49B | 1695.2 |
| ABBV | AbbVie Inc. | $454.79B | 109.1 |
| MRK | Merck & Co., Inc. | $320.56B | 17.8 |
| AMGN | AMGEN INC | $209.21B | 27.2 |
| ABT | ABBOTT LABORATORIES | $183.95B | 28.4 |
| GILD | GILEAD SCIENCES, INC. | $162.99B | 19.4 |
| PFE | PFIZER INC | $141.97B | 18.3 |
| SYK | STRYKER CORP | $133.42B | 41.4 |
| BMY | BRISTOL MYERS SQUIBB CO | $132.49B | 18.7 |
| ISRG | INTUITIVE SURGICAL INC | $124.70B | 44.9 |
